Cancer Letters
Volume 241, Issue 1 , Pages 1-12 , 8 September 2006

Endocrine disrupting compounds and prostate cancer

  • J.K. Hess-Wilson

      Affiliations

    • Department of Cell Biology, University of Cincinnati College of Medicine, P.O. Box 670521, 3125 Eden Ave., Cincinnati, OH 45267-0521, USA
    • ,
  • K.E. Knudsen

      Affiliations

    • Department of Cell Biology, University of Cincinnati College of Medicine, P.O. Box 670521, 3125 Eden Ave., Cincinnati, OH 45267-0521, USA
    • Center for Environmental Genetics, University of Cincinnati College of Medicine, Cincinnati, OH 45267-0521, USA
    • Corresponding Author InformationCorresponding author.Address: Department of Cell Biology, University of Cincinnati College of Medicine, P.O. Box 670521, 3125 Eden Ave., Cincinnati, OH 45267-0521, USA. Tel.: +1 513 558 7371; fax: +1 513 558 4454.

Received 26 September 2005 ,Accepted 7 October 2005.

References 

  1. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, et al. Cancer statistics, 2005. CA Cancer J. Clin. 2005;55(1):10–30
  2. Trapman J, Brinkmann OA. The androgen receptor in prostate cancer. Pathol. Res. Pract. 1996;192(7):752–760
  3. Goodin S, Rao VK, DiPaola RS. State-of-the-art treatment of metastatic hormone-refractory prostate cancer. Oncologist. 2002;7(4):360–370
  4. Feldman BJ, Feldman D. The development of androgen-independent prostate cancer. Nat. Rev. Cancer. 2001;1(1):34–45
  5. Leewansangtong S, Soontrapa S. Hormonal ablation therapy for metastatic prostatic carcinoma: a review. J. Med. Assoc. Thai. 1999;82(2):192–205
  6. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, et al. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology. 1995;136(2):796–803
  7. Reid P, Kantoff P, Oh W. Antiandrogens in prostate cancer. Invest. New Drugs. 1999;17(3):271–284
  8. Russell DW, Wilson JD. Steroid 5 alpha-reductase: two genes/two enzymes. Annu. Rev. Biochem. 1994;63:25–61
  9. Russell DW, Berman DM, Bryant JT, Cala KM, Davis DL, Landrum CP, et al. The molecular genetics of steroid 5 alpha-reductases. Recent Prog. Horm. Res. 1994;49:275–284
  10. Stephan C, Jung K, Diamandis EP, Rittenhouse HG, Lein M, Loening SA. Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. Urology. 2002;59(1):2–8
  11. Klotz L. Hormone therapy for patients with prostate carcinoma. Cancer. 2000;88(12):3009–3014
  12. Craft N, Sawyers CL. Mechanistic concepts in androgen-dependence of prostate cancer. Cancer Metastasis Rev. 1998;17(4):421–427
  13. Visakorpi T, Hyytinen E, Koivisto P, Tanner M, Keinanen R, Palmberg C, et al. In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet. 1995;9(4):401–406
  14. Culig Z, Steiner H, Bartsch G, Hobisch A. Mechanisms of endocrine therapy-responsive and -unresponsive prostate tumours. Endocr. Relat. Cancer. 2005;12(2):229–244
  15. Navarro D, Luzardo OP, Fernandez L, Chesa N, Diaz-Chico BN. Transition to androgen-independence in prostate cancer. J. Steroid Biochem. Mol. Biol. 2002;81(3):191–201
  16. Koivisto P, Kononen J, Palmberg C, Tammela T, Hyytinen E, Isola J, et al. Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. Cancer Res. 1997;57(2):314–319
  17. Chen CD, Welsbie DS, Tran C, Baek SH, Chen R, Vessella R, et al. Molecular determinants of resistance to antiandrogen therapy. Nat. Med. 2004;10(1):33–39
  18. Gregory CW, He B, Johnson RT, Ford OH, Mohler JL, French FS, et al. A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. Cancer Res. 2001;61(11):4315–4319
  19. Fujimoto N, Mizokami A, Harada S, Matsumoto T. Different expression of androgen receptor coactivators in human prostate. Urology. 2001;58(2):289–294
  20. Chatterjee B. The role of the androgen receptor in the development of prostatic hyperplasia and prostate cancer. Mol. Cell Biochem. 2003;253(1–2):89–101
  21. Shih A, Zhang S, Cao HJ, Boswell S, Wu YH, Tang HY, et al. Inhibitory effect of epidermal growth factor on resveratrol-induced apoptosis in prostate cancer cells is mediated by protein kinase C-alpha. Mol. Cancer Ther. 2004;3(11):1355–1364
  22. Suzuki H, Sato N, Watabe Y, Masai M, Seino S, Shimazaki J. Androgen receptor gene mutations in human prostate cancer. J. Steroid Biochem. Mol. Biol. 1993;46(6):759–765
  23. Culig Z, Hobisch A, Cronauer MV, Cato AC, Hittmair A, Radmayr C, et al. Mutant androgen receptor detected in an advanced-stage prostatic carcinoma is activated by adrenal androgens and progesterone. Mol. Endocrinol. 1993;7(12):1541–1550
  24. Gottlieb B, Beitel LK, Wu JH, Trifiro M. The androgen receptor gene mutations database (ARDB): 2004 update. Hum. Mutat. 2004;23(6):527–533
  25. Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, et al. Functional characterization of mutant androgen receptors from androgen-independent prostate cancer. Clin. Cancer Res. 1997;3(8):1383–1388
  26. Hara T, Miyazaki J, Araki H, Yamaoka M, Kanzaki N, Kusaka M, et al. Novel mutations of androgen receptor: a possible mechanism of bicalutamide withdrawal syndrome. Cancer Res. 2003;63(1):149–153
  27. Bohl CE, Gao W, Miller DD, Bell CE, Dalton JT. Structural basis for antagonism and resistance of bicalutamide in prostate cancer. Proc. Natl Acad. Sci. USA. 2005;102(17):6201–6206
  28. Welshons WV, Thayer KA, Judy BM, Taylor JA, Curran EM, vom Saal FS. Large effects from small exposures. I. Mechanisms for endocrine-disrupting chemicals with estrogenic activity. Environ. Health Perspect. 2003;111(8):994–1006
  29. Jarred RA, Cancilla B, Prins GS, Thayer KA, Cunha GR, Risbridger GP. Evidence that estrogens directly alter androgen-regulated prostate development. Endocrinology. 2000;141(9):3471–3477
  30. Basly JP, Lavier MC. Dietary phytoestrogens: potential selective estrogen enzyme modulators?. Planta Med. 2005;71(4):287–294
  31. Piersen CE. Phytoestrogens in botanical dietary supplements: implications for cancer. Integr. Cancer Ther. 2003;2(2):120–138
  32. Fitzpatrick LA. Alternatives to estrogen. Med. Clin. North Am. 2003;87(5):1091–1113
  33. Rowland I, Faughnan M, Hoey L, Wahala K, Williamson G, Cassidy A. Bioavailability of phyto-oestrogens. Br. J. Nutr. 2003;89(Suppl 1):S45–S58
  34. Wang LQ. Mammalian phytoestrogens: enterodiol and enterolactone. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 2002;777(1–2):289–309
  35. Olea N, Pazos P, Exposito J. Inadvertent exposure to xenoestrogens. Eur. J. Cancer Prev. 1998;7(Suppl 1):S17–S23
  36. Singleton DW, Khan SA. Xenoestrogen exposure and mechanisms of endocrine disruption. Front. Biosci. 2003;8:s110–s118
  37. Oh WK. The evolving role of estrogen therapy in prostate cancer. Clin. Prostate Cancer. 2002;1(2):81–89
  38. Keam SJ, Wagstaff AJ. Ethinylestradiol/drospirenone: a review of its use as an oral contraceptive. Treat. Endocrinol. 2003;2(1):49–70
  39. Mitchell S, Abel P, Ware M, Stamp G, Lalani E. Phenotypic and genotypic characterization of commonly used human prostatic cell lines. Br. J. Urol. Int. 2000;85(7):932–944
  40. Haighton LA, Hlywka JJ, Doull J, Kroes R, Lynch BS, Munro IC. An evaluation of the possible carcinogenicity of bisphenol A to humans. Regul. Toxicol. Pharmacol. 2002;1:238–254
  41. Ruse ND. Xenoestrogenicity and dental materials. J. Can. Dent. Assoc. 1997;63(11):833–836
  42. Calafat AM, Kuklenyik Z, Reidy JA, Caudill SP, Ekong J, Needham LL. Urinary concentrations of bisphenol A and 4-nonylphenol in a human reference population. Environ. Health Perspect. 2005;113(4):391–395
  43. Longnecker MP, Rogan WJ, Lucier G. The human health effects of DDT (dichlorodiphenyltrichloroethane) and PCBS (polychlorinated biphenyls) and an overview of organochlorines in public health. Annu. Rev. Public Health. 1997;18:211–244
  44. Kelce WR, Stone CR, Laws SC, Gray LE, Kemppainen JA, Wilson EM. Persistent DDT metabolite p,p’-DDE is a potent androgen receptor antagonist. Nature. 1995;375(6532):581–585
  45. Ying GG, Williams B, Kookana R. Environmental fate of alkylphenols and alkylphenol ethoxylates–a review. Environ. Int. 2002;28(3):215–226
  46. Mueller SO. Xenoestrogens: mechanisms of action and detection methods. Anal. Bioanal. Chem. 2004;378(3):582–587
  47. vom Saal FS, Timms BG, Montano MM, Palanza P, Thayer KA, Nagel SC, et al. Prostate enlargement in mice due to fetal exposure to low doses of estradiol or diethylstilbestrol and opposite effects at high doses. Proc. Natl Acad. Sci. USA. 1997;94(5):2056–2061
  48. vom Saal FS, Hughes C. An extensive new literature concerning low-dose effects of bisphenol A shows the need for a new risk assessment. Environ. Health Perspect. 2005;113(8):926–933
  49. Purchase IF. Fraud, errors and gamesmanship in experimental toxicology. Toxicology. 2004;202(1–2):1–20
  50. Milman HA, Bosland MC, Walden PD, Heinze JE. Evaluation of the adequacy of published studies of low-dose effects of bisphenol A on the rodent prostate for use in human risk assessment. Regul. Toxicol. Pharmacol. 2002;35(3):338–346
  51. Pflieger-Bruss S, Schuppe HC, Schill WB. The male reproductive system and its susceptibility to endocrine disrupting chemicals. Andrologia. 2004;36(6):337–345
  52. Ashby J, Tinwell H, Odum J, Lefevre P. Natural variability and the influence of concurrent control values on the detection and interpretation of low-dose or weak endocrine toxicities. Environ. Health Perspect. 2004;112(8):847–853
  53. Gupta C. Reproductive malformation of the male offspring following maternal exposure to estrogenic chemicals. Proc. Soc. Exp. Biol. Med. 2000;224(2):61–68
  54. Gupta C. The role of estrogen receptor, androgen receptor and growth factors in diethylstilbestrol-induced programming of prostate differentiation. Urol. Res. 2000;28(4):223–229
  55. Timms BG, Howdeshell KL, Barton L, Bradley S, Richter CA, vom Saal FS. Estrogenic chemicals in plastic and oral contraceptives disrupt development of the fetal mouse prostate and urethra. Proc. Natl Acad. Sci. USA. 2005;102(19):7014–7019
  56. Thayer KA, Ruhlen RL, Howdeshell KL, Buchanan DL, Cooke PS, Preziosi D, et al. Altered prostate growth and daily sperm production in male mice exposed prenatally to subclinical doses of 17alpha-ethinyl oestradiol. Hum. Reprod. 2001;16(5):988–996
  57. Ralph JL, Orgebin-Crist MC, Lareyre JJ, Nelson CC. Disruption of androgen regulation in the prostate by the environmental contaminant hexachlorobenzene. Environ. Health Perspect. 2003;111(4):461–466
  58. Ramos JG, Varayoud J, Sonnenschein C, Soto AM, Munoz De Toro M, Luque EH. Prenatal exposure to low doses of bisphenol A alters the periductal stroma and glandular cell function in the rat ventral prostate. Biol. Reprod. 2001;65(4):1271–1277
  59. Tinwell H, Haseman J, Lefevre PA, Wallis N, Ashby J. Normal sexual development of two strains of rat exposed in utero to low doses of bisphenol A. Toxicol. Sci. 2002;68(2):339–348
  60. Yoshino H, Ichihara T, Kawabe M, Imai N, Hagiwara A, Asamoto M, et al. Lack of significant alteration in the prostate or testis of F344 rat offspring after transplacental and lactational exposure to bisphenol A. J. Toxicol. Sci. 2002;27(5):433–439
  61. Vom Saal FS, Nagel SC, Timms BG, Welshons WV. Implications for human health of the extensive bisphenol a literature showing adverse effects at low doses: a response to attempts to mislead the public. Toxicology. 2005;212(2/3):244–252
  62. Putz O, Schwartz CB, Kim S, LeBlanc GA, Cooper RL, Prins GS. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat: I. Effects on the prostate gland. Biol. Reprod. 2001;65(5):1496–1505
  63. Putz O, Schwartz CB, LeBlanc GA, Cooper RL, Prins GS. Neonatal low- and high-dose exposure to estradiol benzoate in the male rat: II. Effects on male puberty and the reproductive tract. Biol. Reprod. 2001;65(5):1506–1517
  64. Lee PC. Disruption of male reproductive tract development by administration of the xenoestrogen, nonylphenol, to male newborn rats. Endocrine. 1998;9(1):105–111
  65. Odum J, Ashby J. Neonatal exposure of male rats to nonylphenol has no effect on the reproductive tract. Toxicol. Sci. 2000;56(2):400–404
  66. Ramos JG, Varayoud J, Kass L, Rodriguez H, Costabel L, Munoz-De-Toro M, et al. Bisphenol a induces both transient and permanent histofunctional alterations of the hypothalamic–pituitary–gonadal axis in prenatally exposed male rats. Endocrinology. 2003;144(7):3206–3215
  67. Woodham C, Birch L, Prins GS. Neonatal estrogen down-regulates prostatic androgen receptor through a proteosome-mediated protein degradation pathway. Endocrinology. 2003;144(11):4841–4850
  68. McLachlan JA. Environmental signaling: what embryos and evolution teach us about endocrine disrupting chemicals. Endocr. Rev. 2001;22(3):319–341
  69. Swan SH, Main KM, Liu F, Stewart SL, Kruse RL, Calafat AM, et al. Decrease in anogenital distance among male infants with prenatal phthalate exposure. Environ. Health Perspect. 2005;113(8):1056–1061
  70. Castellon E, Venegas K, Saenz L, Contreras H, Huidobro C. Secretion of prostatic specific antigen, proliferative activity and androgen response in epithelial-stromal co-cultures from human prostate carcinoma. Int. J. Androl. 2005;28(1):39–46
  71. Condon MS. The role of the stromal microenvironment in prostate cancer. Semin. Cancer Biol. 2005;15(2):132–137
  72. Condon MS, Bosland MC. The role of stromal cells in prostate cancer development and progression. In Vivo. 1999;13(1):61–65
  73. Wetherill YB, Petre CE, Monk KR, Puga A, Knudsen KE. The xenoestrogen bisphenol A induces inappropriate androgen receptor activation and mitogenesis in prostatic adenocarcinoma cells. Mol. Cancer Ther. 2002;1(7):515–524
  74. Wetherill YB, Fisher NL, Staubach A, Danielsen M, de Vere White RW, Knudsen KE. Xenoestrogen action in prostate cancer: pleiotropic effects dependent on androgen receptor status. Cancer Res. 2005;65(1):54–65
  75. Schrader TJ, Cooke GM. Examination of selected food additives and organochlorine food contaminants for androgenic activity in vitro. Toxicol. Sci. 2000;53(2):278–288
  76. Verougstraete V, Lison D, Hotz P. Cadmium, lung and prostate cancer: a systematic review of recent epidemiological data. J. Toxicol. Environ. Health B Crit. Rev. 2003;6(3):227–255
  77. Sahmoun AE, Case LD, Jackson SA, Schwartz GG. Cadmium and prostate cancer: a critical epidemiologic analysis. Cancer Invest. 2005;23(3):256–263
  78. Henson MC, Chedrese PJ. Endocrine disruption by cadmium, a common environmental toxicant with paradoxical effects on reproduction. Exp. Biol. Med. (Maywood). 2004;229(5):383–392
  79. Jaga K, Dharmani C. Global surveillance of DDT and DDE levels in human tissues. Int. J. Occup. Med. Environ. Health. 2003;16(1):7–20
  80. Maggiolini M, Vivacqua A, Carpino A, Bonofiglio D, Fasanella G, Salerno M, et al. The mutant androgen receptor T877A mediates the proliferative but not the cytotoxic dose-dependent effects of genistein and quercetin on human LNCaP prostate cancer cells. Mol. Pharmacol. 2002;62(5):1027–1035
  81. Mitchell SH, Zhu W, Young CY. Resveratrol inhibits the expression and function of the androgen receptor in LNCaP prostate cancer cells. Cancer Res. 1999;59(23):5892–5895
  82. Davis JN, Kucuk O, Sarkar FH. Expression of prostate-specific antigen is transcriptionally regulated by genistein in prostate cancer cells. Mol. Carcinog. 2002;34(2):91–101
  83. Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J. Steroid Biochem. Mol. Biol. 2004;92(4):265–271
  84. Routledge EJ, White R, Parker MG, Sumpter JP. Differential effects of xenoestrogens on coactivator recruitment by estrogen receptor (ER) alpha and ERbeta. J. Biol. Chem. 2000;275(46):35986–35993
  85. Inoshita H, Masuyama H, Hiramatsu Y. The different effects of endocrine-disrupting chemicals on estrogen receptor-mediated transcription through interaction with coactivator TRAP220 in uterine tissue. J. Mol. Endocrinol. 2003;31(3):551–561
  86. Gao S, Liu GZ, Wang Z. Modulation of androgen receptor-dependent transcription by resveratrol and genistein in prostate cancer cells. Prostate. 2004;59(2):214–225
  87. Herath CB, Jin W, Watanabe G, Arai K, Suzuki AK, Taya K. Adverse effects of environmental toxicants, octylphenol and bisphenol A, on male reproductive functions in pubertal rats. Endocrine. 2004;25(2):163–172
  88. Ivett JL, Brown BM, Rodgers C, Anderson BE, Resnick MA, Zeiger E. Chromosomal aberrations and sister chromatid exchange tests in Chinese hamster ovary cells in vitro. IV. Results with 15 chemicals. Environ. Mol. Mutagen. 1989;14(3):165–187
  89. Schweikl H, Schmalz G, Rackebrandt K. The mutagenic activity of unpolymerized resin monomers in salmonella typhimurium and V79 cells. Mutat. Res. 1998;415(1/2):119–130
  90. Hunt PA, Koehler KE, Susiarjo M, Hodges CA, Ilagan A, Voigt RC, et al. Bisphenol a exposure causes meiotic aneuploidy in the female mouse. Curr. Biol. 2003;13(7):546–553
  91. Pfeiffer E, Rosenberg B, Deuschel S, Metzler M. Interference with microtubules and induction of micronuclei in vitro by various bisphenols. Mutat. Res. 1997;390(1–2):21–31
  92. Lehmann L, Metzler M. Bisphenol A and its methylated congeners inhibit growth and interfere with microtubules in human fibroblasts in vitro. Chem. Biol. Interact. 2004;147(3):273–285
  93. Nakagomi M, Suzuki E, Usumi K, Saitoh Y, Yoshimura S, Nagao T, et al. Effects of endocrine disrupting chemicals on the microtubule network in chinese hamster V79 cells in culture and in sertoli cells in rats. Teratog. Carcinog. Mutagen. 2001;21(6):453–462
  94. Ochi T. Induction of multiple microtubule-organizing centers, multipolar spindles and multipolar division in cultured V79 cells exposed to diethylstilbestrol, estradiol-17beta and bisphenol A. Mutat. Res. 1999;431(1):105–121
  95. Metzler M, Pfeiffer E. Effects of estrogens on microtubule polymerization in vitro: correlation with estrogenicity. Environ. Health Perspect. 1995;103(Suppl. 7):21–22
  96. Tsutsui T, Tamura Y, Yagi E, Hasegawa K, Takahashi M, Maizumi N, et al. Bisphenol-A induces cellular transformation, aneuploidy and DNA adduct formation in cultured syrian hamster embryo cells. Int. J. Cancer. 1998;75(2):290–294
  97. Tsutsui T, Tamura Y, Yagi E, Barrett JC. Involvement of genotoxic effects in the initiation of estrogen-induced cellular transformation: studies using syrian hamster embryo cells treated with 17beta-estradiol and eight of its metabolites. Int. J. Cancer. 2000;86(1):8–14
  98. Takahashi S, Chi XJ, Yamaguchi Y, Suzuki H, Sugaya S, Kita K, et al. Mutagenicity of bisphenol A and its suppression by interferon-alpha in human RSa cells. Mutat. Res. 2001;490(2):199–207
  99. Atkinson A, Roy D. In vivo DNA adduct formation by bisphenol A. Environ. Mol. Mutagen. 1995;26(1):60–66
  100. Waalkes MP, Anver M, Diwan BA. Carcinogenic effects of cadmium in the noble (NBL/Cr) rat: induction of pituitary, testicular, and injection site tumors and intraepithelial proliferative lesions of the dorsolateral prostate. Toxicol. Sci. 1999;52(2):154–161
  101. Waalkes MP, Anver MR, Diwan BA. Chronic toxic and carcinogenic effects of oral cadmium in the Noble (NBL/Cr) rat: induction of neoplastic and proliferative lesions of the adrenal, kidney, prostate, and testes. J. Toxicol. Environ. Health A. 1999;58(4):199–214
  102. Achanzar WE, Diwan BA, Liu J, Quader ST, Webber MM, Waalkes MP. Cadmium-induced malignant transformation of human prostate epithelial cells. Cancer Res. 2001;61(2):455–458
  103. Anway MD, Cupp AS, Uzumcu M, Skinner MK. Epigenetic transgenerational actions of endocrine disruptors and male fertility. Science. 2005;308(5727):1466–1469
  104. Moore NP. The oestrogenic potential of the phthalate esters. Reprod. Toxicol. 2000;14(3):183–192
  105. Fisher JS. Are all EDC effects mediated via steroid hormone receptors?. Toxicology. 2004;205(1–2):33–41
  106. Yatani R, Chigusa I, Akazaki K, Stemmermann GN, Welsh RA, Correa P. Geographic pathology of latent prostatic carcinoma. Int. J. Cancer. 1982;29(6):611–616
  107. Adlercreutz H, Honjo H, Higashi A, Fotsis T, Hamalainen E, Hasegawa T, et al. Urinary excretion of lignans and isoflavonoid phytoestrogens in Japanese men and women consuming a traditional Japanese diet. Am. J. Clin. Nutr. 1991;54(6):1093–1100
  108. Adlercreutz H. Epidemiology of phytoestrogens. Baillieres Clin. Endocrinol. Metab. 1998;12(4):605–623
  109. Severson RK, Nomura AM, Grove JS, Stemmermann GN. A prospective study of demographics, diet, and prostate cancer among men of Japanese Ancestry in Hawaii. Cancer Res. 1989;49(7):1857–1860
  110. Mills PK, Beeson WL, Phillips RL, Fraser GE. Cohort study of diet, lifestyle, and prostate cancer in adventist men. Cancer. 1989;64(3):598–604
  111. Hirayama T. Nutrition and cancer–a large scale cohort study. Prog. Clin. Biol. Res. 1986;206:299–311
  112. Graham S, Haughey B, Marshall J, Priore R, Byers T, Rzepka T, et al. Diet in the epidemiology of carcinoma of the prostate gland. J. Natl Cancer Inst. 1983;70(4):687–692
  113. Giovannucci E, Ascherio A, Rimm EB, Stampfer MJ, Colditz GA, Willett WC. Intake of carotenoids and retinol in relation to risk of prostate cancer. J. Natl Cancer Inst. 1995;87(23):1767–1776
  114. Clinton SK. Lycopene: chemistry, biology, and implications for human health and disease. Nutr. Rev. 1998;1(2 Pt 1):35–51
  115. Kolonel LN, Nomura AM, Cooney RV. Dietary fat and prostate cancer: current status. J. Natl Cancer Inst. 1999;91(5):414–428
  116. Cohen JH, Kristal AR, Stanford JL. Fruit and vegetable intakes and prostate cancer risk. J. Natl Cancer Inst. 2000;92(1):61–68
  117. Strom SS, Yamamura Y, Duphorne CM, Spitz MR, Babaian RJ, Pillow PC, et al. Phytoestrogen intake and prostate cancer: a case-control study using a new database. Nutr. Cancer. 1999;33(1):20–25
  118. Nagata C. Ecological study of the association between soy product intake and mortality from cancer and heart disease in Japan. Int. J. Epidemiol. 2000;29(5):832–836
  119. Habito RC, Montalto J, Leslie E, Ball MJ. Effects of replacing meat with soyabean in the diet on sex hormone concentrations in healthy adult males. Br. J. Nutr. 2000;84(4):557–563
  120. Nagata C, Takatsuka N, Shimizu H, Hayashi H, Akamatsu T, Murase K. Effect of soymilk consumption on serum estrogen and androgen concentrations in japanese men. Cancer Epidemiol. Biomarkers Prev. 2001;10(3):179–184
  121. Allen NE, Appleby PN, Davey GK, Key TJ. Soy milk intake in relation to serum sex hormone levels in British men. Nutr. Cancer. 2001;41(1/2):41–46
  122. Pollard M, Luckert PH. Influence of isoflavones in soy protein isolates on development of induced prostate-related cancers in L-W rats. Nutr. Cancer. 1997;28(1):41–45
  123. Pollard M. Prevention of prostate-related cancers in lobund-wistar rats. Prostate. 1999;39(4):305–309
  124. Onozawa M, Kawamori T, Baba M, Fukuda K, Toda T, Sato H, et al. Effects of a soybean isoflavone mixture on carcinogenesis in prostate and seminal vesicles of F344 rats. Jpn. J. Cancer Res. 1999;90(4):393–398
  125. Landstrom M, Zhang JX, Hallmans G, Aman P, Bergh A, Damber JE, et al. Inhibitory effects of soy and rye diets on the development of dunning R3327 prostate adenocarcinoma in rats. Prostate. 1998;36(3):151–161
  126. Bylund A, Zhang JX, Bergh A, Damber JE, Widmark A, Johansson A, et al. Rye bran and soy protein delay growth and increase apoptosis of human LNCaP prostate adenocarcinoma in nude mice. Prostate. 2000;42(4):304–314
  127. Pollard M, Wolter W. Prevention of spontaneous prostate-related cancer in lobund-wistar rats by a soy protein isolate/isoflavone diet. Prostate. 2000;45(2):101–105
  128. Mentor-Marcel R, Lamartiniere CA, Eltoum IE, Greenberg NM, Elgavish A. Genistein in the diet reduces the incidence of poorly differentiated prostatic adenocarcinoma in transgenic mice (TRAMP). Cancer Res. 2001;61(18):6777–6782
  129. Fritz WA, Wang J, Eltoum IE, Lamartiniere CA. Dietary genistein down-regulates androgen and estrogen receptor expression in the rat prostate. Mol. Cell. Endocrinol. 2002;186(1):89–99
  130. Jang M, Pezzuto JM. Cancer chemopreventive activity of resveratrol. Drugs Exp. Clin. Res. 1999;25(2/3):65–77
  131. Hussain M, Banerjee M, Sarkar FH, Djuric Z, Pollak MN, Doerge D, et al. Soy isoflavones in the treatment of prostate cancer. Nutr. Cancer. 2003;47(2):111–117
  132. Stephens FO. Phytoestrogens and prostate cancer: possible preventive role. Med. J. Aust. 1997;167(3):138–140
  133. Adlercreutz H, Mazur W. Phyto-oestrogens and western diseases. Ann. Med. 1997;29(2):95–120
  134. Kurzer MS, Xu X. Dietary phytoestrogens. Annu. Rev. Nutr. 1997;17:353–381
  135. Demark-Wahnefried W, Price DT, Polascik TJ, Robertson CN, Anderson EE, Paulson DF, et al. Pilot study of dietary fat restriction and flaxseed supplementation in men with prostate cancer before surgery: exploring the effects on hormonal levels, prostate-specific antigen, and histopathologic features. Urology. 2001;58(1):47–52
  136. Weber KS, Setchell KD, Stocco DM, Lephart ED. Dietary soy-phytoestrogens decrease testosterone levels and prostate weight without altering LH, prostate 5alpha-reductase or testicular steroidogenic acute regulatory peptide levels in adult male sprague-dawley rats. J. Endocrinol. 2001;170(3):591–599
  137. Kato K, Takahashi S, Cui L, Toda T, Suzuki S, Futakuchi M, et al. Suppressive effects of dietary genistin and daidzin on rat prostate carcinogenesis. Jpn. J. Cancer Res. 2000;91(8):786–791
  138. Lin X, Switzer BR, Demark-Wahnefried W. Effect of mammalian lignans on the growth of prostate cancer cell lines. Anticancer Res. 2001;21(6A):3995–3999
  139. Magee PJ, Rowland IR. Phyto-oestrogens, their mechanism of action: current evidence for a role in breast and prostate cancer. Br. J. Nutr. 2004;91(4):513–531
  140. Mitchell JH, Duthie SJ, Collins AR. Effects of phytoestrogens on growth and DNA integrity in human prostate tumor cell lines: PC-3 and LNCaP. Nutr. Cancer. 2000;38(2):223–228
  141. Kim YA, Rhee SH, Park KY, Choi YH. Antiproliferative effect of resveratrol in human prostate carcinoma cells. J. Med. Food. 2003;6(4):273–280
  142. Hempstock J, Kavanagh JP, George NJ. Growth inhibition of prostate cell lines in vitro by phyto-oestrogens. Br. J. Urol. 1998;82(4):560–563
  143. Peterson G, Barnes S. Genistein and biochanin A inhibit the growth of human prostate cancer cells but not epidermal growth factor receptor tyrosine autophosphorylation. Prostate. 1993;22(4):335–345
  144. Naik HR, Lehr JE, Pienta KJ. An in vitro and in vivo study of antitumor effects of genistein on hormone refractory prostate cancer. Anticancer Res. 1994;14(6B):2617–2619
  145. Santibanez JF, Navarro A, Martinez J. Genistein inhibits proliferation and in vitro invasive potential of human prostatic cancer cell lines. Anticancer Res. 1997;17(2A):1199–1204
  146. Davis JN, Muqim N, Bhuiyan M, Kucuk O, Pienta KJ, Sarkar FH. Inhibition of prostate specific antigen expression by genistein in prostate cancer cells. Int. J. Oncol. 2000;16(6):1091–1097

PII: S0304-3835(05)00915-8

doi: 10.1016/j.canlet.2005.10.006

Cancer Letters
Volume 241, Issue 1 , Pages 1-12 , 8 September 2006

Article Tools

* Image Usage & Resolution